Procter & Gamble Co. (P&G;, NYSE: PG) is a Fortune 500 American multinational corporation headquartered in Downtown Cincinnati, Ohio that manufactures a wide range of consumer goods. It is 6th in Fortune's Most Admired Companies 2010 list. P&G; is credited with many business innovations including brand management and the soap opera.
Figures are based on itemized contributions reported to the Federal Election Commission and state agencies. Please note that:
- contributions under $200 are not reported, and so are not included in totals.
- only contributions from individuals and organizations to candidates are included. Various accounting measures and more exotic contribution types are excluded.
- contributions are matched based on organization and recipient name reported within each election cycle. Contributions using an incorrect or non-standard version of the name may be missed.
- corporate name changes and mergers may cause figures to differ from those of the Center for Responsive Politics.
- organization totals include known subsidiaries of the organization.
Latest FEC Datacovers through committee's March 20, 2009 filing.
Summaryoverview of the committee's finances
- Total Raised:
- Total Spent:
- Cash on Hand:
Standardized Donation Informationcovers roughly through Q4 2012. may lag behind FEC section above, as donors and industries are identified by hand.
- Employee Color Block
- PAC Color Block
Republicans vs. Democratsin dollars. "Other" includes 3rd parties and organizations without official party affiliation.
State vs. Federalin dollars
Top PAC Recipients
- Employee Color Block
- PAC Color Block
Figures are based on lobbying activity reported to the Senate Office of Public Records. Reported dollar amounts are required to be accurate only to the nearest $20,000. For organizations whose primary business is lobbying, we display total income and top clients. For organizations that are not primarily lobbying firms, we display total amount spent on lobbying and top lobbying firms hired.
For more information, please see our lobbying methodology page.
Lobbying on Behalf of Procter & Gamble
Names of Lobbyists
Firm Hired Amount Procter & Gamble $8,578,538
Most Frequently Disclosed Lobbying Issues
- Medicare & Medicaid,
- Health Issues,
- Chemical Industry,
- Food Industry,
- Environment & Superfund,
Most Frequently Disclosed Bills
Bill No. Title H.R.4213 Tax Extenders Act of 2009 S.3551 Fiscally Responsible Relief for Our States Act of 2010 S.510 FDA Food Safety Modernization Act S.2191 S.2355 S.2356 S.2357 S.2358 S.2363 S.2369
RegulationsMentioned in 66 dockets; Submitted to 5 dockets
All data is based on documents downloaded from Regulations.gov. The first table shows mentions: all documents that include the name of the company anywhere in the document or document metadata. The second table shows submissions: all documents where the submitter metadata included the company name. Each table shows the top 10 dockets, ranked by number of occurrences.
Matches are based on a search for the company name. Variations in the company name, such as acronyms, nicknames or alternate names may cause documents to be missed. The mention of a company name in a document may be incidental and does not necessarily indicate that the company has any relevance to the document. Company names that are common English words may erroneously match with text that is not referring to the company.
Not all agencies submit public comments to Regulations.gov. For a list of participating and non-participating agencies see here. Agencies that do submit to Regulations.gov have varying levels of accuracy and completeness.
Regulations and public comments can be downloaded in bulk here.
The tables show occurrences of "Procter & Gamble" in public comments on proposed federal regulations.
Documents Submitted by the Organization
View all submissions data for Procter & Gamble
- Toggle 1 USTR Request for Comments Concerning Free Trade Agreement With the Republic of Colombia 2009
- Toggle 1 FDA Strengthening the Center for Devices and Radiological Health’s 510(k) Review Process; Public Meeting; Request for Comments 2010
- Toggle 1 FDA Joint Meeting of the Drug Safety and Risk Management Advisory Committee, Nonprescription Drugs Advisory Committee, and the Anesthetic and Life Support Drugs Advisory Committee; Notice of Meeting. 2009
- Toggle 1 FDA Petition Regarding the Review of Pending and Future Applications to Market PPIs OTC for Relief of Frequent Heartburn_CLOSED 2009
- Toggle 1 FDA Review and Establish an Appropriate Regulatory Classification for Tooth Whitening Preparations That act by Chemical Means to Lighten Tooth Color 2009
Mentions in Document Text
View all mentions data for Procter & Gamble
- Toggle 6 FDA Petition Regarding the Review of Pending and Future Applications to Market PPIs OTC for Relief of Frequent Heartburn_CLOSED 2009
- Toggle 5 FDA Issue a Bioequivalence Guidance for Mesalamine Delayed-Release Tablets and Refrain From Approving any Abbreviated New Drug Application (ANDA) Referencing Asacol® and/or Asacol® HD Unless the Proposed Generic Product is Shown to be Bioequivalente Based on Appropriate Data 2010
- Toggle 2 FDA To Determine Whether Actonel with Calcium (Copackaged) (Risedronate Sodium and Calcium Carbonate) Manufactured by Procter and Gamble has Been Voluntarily Withdrawn From Sale for Safety or Efficacy Reasons 2010
- Toggle 2 FDA Draft Guidance for Industry on Electronic Source Documentation in Clinical Investigations; Availability 2010
- Toggle 2 EPA Addition of National Toxicology Program Carcinogens; Community Right-to-Know Toxic Chemical Release Reporting 2010
- Toggle 2 USCG Notice of Availability of Final Environmental Impact Statement for the Goethals Bridge Replacement Project 2009
- Toggle 2 CMS Medicaid Prescription Drugs Average Manufacture Price 2010
- Toggle 2 FDA Determine Whether Actonel (Risedronate Sodium) Tablets, 75 mg manufactured by Procter and Gamble has been Voluntarily Withdrawn or Withheld from Sale for Safety or Efficacy Reasons 2010
- Toggle 1 FDA Determine Whether Actonel with Calcium (Risedronate Sodium and Calcium Carbonate (Copackaged) Tablets, 35 mg/500 mg by Procter and Gamble has Been Voluntarily Withdrawn or Withheld From Sale for Safety or Efficacy Reasons 2010
- Toggle 1 EPA Oil and Natural Gas Sector -- New Source Performance Standards, National Emission Standards for Hazardous Air Pollutants, and Control Techniques Guidelines 2010
EPA Violations1 Enforcement Actions
Figures are based on data from the Environmental Protection Agency’s ECHO website. The ECHO database contains federal and state environmental enforcement actions. Data displayed here includes only those actions that began after 2000 and resulted in fines of over $1 million.
Actions where the company was the sole defendant are listed first. Actions where the company is one of multiple defendants are listed subsequently.
For more information see our EPA methodology page.
|Fox River Nrda/Pcb Releases De Minimis (Cercla)||The Procter & Gamble Paper Products Co. (+10 others)||2009||Green Bay, Wi||$1,582,954|
Advisory Committees6 people on 6 committees
Data is based on disclosures required by the Federal Advisory Committee Act (FACA). Matches are based on the occurrence of the company name in the committee member affiliation. Variations in company names may cause some matches to be missed.
The table shows only the top 10 agencies. To search and download raw records from the complete dataset see the FACA data section.
Table shows employees of "Procter & Gamble" that sat on federal advisory committees.
- Toggle Department of State 2 people on 2 committees
- Toggle Department of Health and Human Services 1 person on 1 committee
- Toggle National Science Foundation 1 person on 1 committee
- Toggle Department of Agriculture 1 person on 1 committee
- Toggle Office of the United States Trade Representative 1 person on 1 committee